Sorrento Therape (SRNE)

NASDAQ
1.550
-0.070(-4.32%)
After Hours
1.580
+0.030(+1.935%)
- Real-time Data
  • Volume:
    9,051,464
  • Day's Range:
    1.520 - 1.605
  • 52 wk Range:
    1.150 - 8.200

SRNE Overview

Prev. Close
1.62
Day's Range
1.52-1.605
Revenue
54.99M
Open
1.57
52 wk Range
1.15-8.2
EPS
-1.55
Volume
9,051,464
Market Cap
685.7M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
9,338,601
P/E Ratio
-1.32
Beta
2.21
1-Year Change
-80.2%
Shares Outstanding
442,383,981
Next Earnings Date
Nov 03, 2022
What is your sentiment on Sorrento Therape?
or
Market is currently closed. Voting is open during market hours.

Sorrento Therape News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Sorrento Therape Analysis

Sorrento Therape Company Profile

Sorrento Therape Company Profile

Employees
799

Sorrento Therapeutics, Inc. is a clinical-stage, antibody-centric, biopharmaceutical company developing therapies to treat cancers and COVID-19. The Company’s segments include Sorrento Therapeutics and Scilex. Sorrento Therapeutics segment is organized around Immune-Oncology therapeutic area, leveraging its G-MAB antibody library and targeted delivery modalities to generate cancer therapeutics. The Scilex segment is largely organized around its non-opioid pain management operations. The Company’s immuno-oncology platforms, including key assets such as fully human antibodies (G-MAB library), clinical- stage immuno-cellular therapies (CAR-T, DAR-T), antibody-drug conjugates (ADCs) and clinical-stage oncolytic virus (Seprehvir). The Company is also developing potential antiviral therapies and vaccines against coronaviruses, including Abivertinib, COVI-AMG, COVISHIELD, COVI-MSC and COVIDROPS, and diagnostic test solutions, including COVITRACK and COVISTIX.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyNeutralSellStrong SellStrong Sell
Technical IndicatorsStrong BuyBuyStrong SellStrong SellStrong Sell
SummaryStrong BuyNeutralStrong SellStrong SellStrong Sell
  • 1.70 again, ouch!
    0
    • jeez what a beating, is it never gonna end?
      0
      • so took the 'a' out of the *****
        0
        • they bleeped out the word 'rectl' cancer
          0
          • Dostarlimab from the pharmaceutical company GlaxoSmithKline acheives 100% success in treating patients with *******cancer - 14 patients in one study show no form of *******cancer after the treatment. Wonder what our guys at SRNE are doing, other companies are getting their magic bullets. Good lord if any of you guys own GlaxoSmithKline, good on ya, thats going to get you set for the start of a good life. Hope SRNE jumps on the bandwagon soon enough.
            0
            • I just bought another 1000 shares. research says its a bargain, value = 3.4 a share
              0
              • Respect buddy, average it out.I would love to have my cost price at $1.60, but would need to buy 200,000 shares! haha
                0
            • This compny will reverse split before you see 3 agian just sell.
              3
              • You must be shorting the stock
                0
            • Gents I've gotta level with you, as Crim Jamer mentioned on 18th April 2022, the possibility of SRNE going below $1 seems very much likely...If I had the cash I would definitely buy more and average but the fact is for this to come back to a solid $10 and above range is going to be a waiting period of at least 5 years..hoping the time period is less but things look really f88ked up, pretty much operators manipulating the stock to have us sell off and they can reap this really cheap and then enjoy selling it out at anywhere between $12 - $18, while we look on as twits. Those who can average they should, those who can't lets wait it out.
              0
              • What are you??… a human crystal ball!?!?… 5 years???🤔… you think its gonna be 5 years before anything is approved??
                0
            • This needs to have M&A !!!!!!!!!!!
              0
              • really something else this company and if you notice they haven't promoted any news is like they want this stock to zinc to a dollar level
                1